Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc (ALDX) Covered Calls
Aldeyra Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 71.03%, high versus the past year. ALDX's highest covered call setup is the $1.50 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 134.38% out of the money with 126 days to expiration, a 142.19% return until expiration, and a 411.89% theoretical annualized return. Across the setups shown, annualized returns run from 185.58% to 411.89% at strikes between $1.00 and $1.50, with 126 to 126 days to expiration, as of Nov 13, 2026.
Read more
Running ALDX covered calls helps you generate income from Aldeyra Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ALDX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ALDX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ALDX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ALDX covered call is worth writing.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma.
| 2027-03-19 | 126 | 1.50 | 134.38 | 0.05 | 0.25 | 91.00 | 142.19 | 411.89 | -7.81 | +0.46 | 77 | 0.20 |
| 2027-03-19 | 126 | 1.00 | 56.25 | 0.05 | 0.45 | 41.00 | 64.06 | 185.58 | -7.81 | +0.64 | 330 | 0.40 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank71.03% High
- Market cap (M$)42
- 52 weeks high-88.36%
- 52 weeks low30.19%
- Analyst recommendationStrong Buy
1.40 - Target price$6.60
886.77% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-0.32
- EPS growth next 5 years38.54%
As of Nov 17, 2026